Spero Therapeutics, Inc. Common Stock
SPROSpero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for bacterial infectious diseases. The company's portfolio includes innovative antibiotics aimed at treating multi-drug resistant infections, addressing significant unmet medical needs in infectious disease care.
Company News
Spero Therapeutics and Innovent Biologics announced an exclusive license agreement for SP001 (IBI355), a third-generation anti-CD40L antibody. Spero receives global rights excluding Greater China, with potential milestone payments totaling approximately $1.1 billion plus tiered royalties. Spero plans to initiate a Phase 2 trial in IgG4-related di...
GSK and Spero Therapeutics announced FDA approval of Utebzi (tebipenem pivoxil hydrobromide), the first oral carbapenem antibiotic for treating complicated urinary tract infections including pyelonephritis. The drug demonstrated non-inferiority to intravenous imipenem-cilastatin in Phase 3 trials and is expected to launch in the U.S. by end of 20...
Spero Therapeutics granted 90,000 restricted stock unit awards to a new employee under their 2019 Inducement Equity Incentive Plan, with vesting occurring in four equal annual installments starting December 1, 2025.
Spero Therapeutics announced interim leadership changes, including the appointment of Esther Rajavelu as Interim President and CEO, and Frank Thomas as Chairman of the Board. The company also provided updates on the Phase 3 PIVOT-PO trial of Tebipenem HBr and its financial position.
Spero Therapeutics, a biopharmaceutical company, announced the grant of 227,500 restricted stock unit awards to new employees under its 2019 Inducement Equity Incentive Plan. The RSUs will vest over four years, subject to continued employment.
